



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/453,387	12/02/1999	Thea A Wilkins	23070-095600	2583

20350 7590 04/08/2003

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER	
BAUM, STUART F	
ART UNIT	PAPER NUMBER

1638

DATE MAILED: 04/08/2003


10

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No. 09/453,387	Applicant(s) WILKINS, THEA A
	Examiner Stuart F. Baum	Art Unit 1638
	--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --	
<p>THE REPLY FILED 11 March 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.</p>		
PERIOD FOR REPLY [check either a) or b)]		
<p>a) <input checked="" type="checkbox"/> The period for reply expires <u>5</u> months from the mailing date of the final rejection.</p> <p>b) <input type="checkbox"/> The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.</p> <p>ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).</p>		
<p>Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).</p>		
<p>1. <input type="checkbox"/> A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.</p>		
<p>2. <input checked="" type="checkbox"/> The proposed amendment(s) will not be entered because:</p>		
<p>(a) <input checked="" type="checkbox"/> they raise new issues that would require further consideration and/or search (see NOTE below);</p>		
<p>(b) <input type="checkbox"/> they raise the issue of new matter (see Note below);</p>		
<p>(c) <input type="checkbox"/> they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or</p>		
<p>(d) <input type="checkbox"/> they present additional claims without canceling a corresponding number of finally rejected claims.</p>		
<p>NOTE: <u>See Continuation Sheet</u>.</p>		
<p>3. <input type="checkbox"/> Applicant's reply has overcome the following rejection(s): _____. </p>		
<p>4. <input type="checkbox"/> Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).</p>		
<p>5. <input checked="" type="checkbox"/> The a)<input checked="" type="checkbox"/> affidavit, b)<input type="checkbox"/> exhibit, or c)<input checked="" type="checkbox"/> request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u>.</p>		
<p>6. <input type="checkbox"/> The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.</p>		
<p>7. <input checked="" type="checkbox"/> For purposes of Appeal, the proposed amendment(s) a)<input checked="" type="checkbox"/> will not be entered or b)<input type="checkbox"/> will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.</p>		
<p>The status of the claim(s) is (or will be) as follows:</p>		
<p>Claim(s) allowed: _____. </p>		
<p>Claim(s) objected to: _____. </p>		
<p>Claim(s) rejected: <u>1,3,5, 7-11, 13, 15 and 17-20</u>. </p>		
<p>Claim(s) withdrawn from consideration: <u>4,6,14,16 and 21-26</u>.</p>		
<p>8. <input type="checkbox"/> The proposed drawing correction filed on ____ is a)<input type="checkbox"/> approved or b)<input type="checkbox"/> disapproved by the Examiner.</p>		
<p>9. <input type="checkbox"/> Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____. </p>		
<p>10. <input type="checkbox"/> Other: _____. </p>		
<p>Stuart F. Baum Ph.D.</p>		

Continuation of 2. NOTE: In claims 1 and 11, claim amendments reciting "a cotton MYB" bring up new issues of 112 2nd paragraph and 112 1st paragraph rejections .

Continuation of 5. does NOT place the application in condition for allowance because: Applicants have not provided support for a cotto MYB polypeptide that is at least 80% identical to SEQ ID NO:1 and has the same function as SEQ ID NO:1. Applicant provide a Declaration that states the DNA binding domain (DBD) of Gh MYB1 exhibits 98% sequence identity to the DBD of G. arboreum, but they don't present data as to the sequence identity between the two homologues, over the whole amino acid sequence. Otherwise arguments are duplicative of previous argument. .


ELIZABETH F. McELWAIN
PRIMARY EXAMINER
GROUP 1800